A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL OF 6-MONTH OF ABATACEPT VS PLACEBO AS ADJUVANT TO PEANUT ORAL IMMUNOTHERAPY TO INDUCE IMMUNOLOGIC CHANGES IN PATIENTS WITH SEVERE PERSISTENT PEANUT ALLERGY (ATARI)
- Registry ID
- CITO-2021-01
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- CHU SAINTE JUSTINE
- Start date
- 2022-02-24
- Last update
- 2021-08-19
Conditions
Related clinical trials
- A PHASE 2, OPEN LABEL STUDY TO ASSESS AD LIB CONSUMPTION OF PEANUT IN PEANUT ALLERGIC INFANTS 6-THROUGH 12-MONTHS-OLD WITH EPICUTANEOUS IMMUNOTHERAPY WITH DBV712 250 UG (THRIVE)
- A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO ASSESS THE
SAFETY OF EPICUTANEOUS IMMUNOTHERAPY WITH DBV712 250 ¿G IN 1-THROUGH 3-YEAR OLD CHILDREN WITH PEANUT ALLERGY (COMFORT TODDLERS)
- A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF EPICUTANEOUS IMMUNOTHERAPY WITH DBV712 250 PG IN 4-7- YEAR-OLD CHILDREN WITH PEANUT ALLERGY
- A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY IN PEDIATRIC PATIENTS WITH PEANUT ALLERGY.
- A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III TRIAL TO ASSESS THE SAFETY AND EFFICACY OF VIASKIN PEANUT IN PEANUT-ALLERGIC YOUNG CHILDREN 1-3 YEARS OF AGE (EPITOPE STUDY)
- REAL-WORLD AR101 MARKET-SUPPORTING EXPERIENCE STUDY IN PEANUT-ALLERGIC CHILDREN, ACTIVE TREATMENT ARM OPEN-LABEL EXTENSION STUDY (RAMSES OLE)
View on source registry